论文部分内容阅读
目的研究S100β、髓鞘碱性蛋白(MBP)含量的变化与糖尿病患者周围神经病变的关系及其意义。方法 60例糖尿病患者分为糖尿病无神经病变组(n=30)和糖尿病并发神经病变组(n=30),并纳入30例健康者作为健康对照组。上述研究对象血清中S100β、MBP含量以酶联免疫吸附法检测。结果糖尿病并发周围神经病变组血清S100β、MBP阳性率较健康对照组和无神经病变组均升高,差异有统计学意义(P<0.05)。结论血清MBP及S100β蛋白测定可能成为糖尿病周围神经病变的早期诊断和随访指标之一。
Objective To study the relationship between the changes of S100β, MBP and peripheral neuropathy in diabetic patients and its significance. Methods Sixty diabetic patients with diabetes mellitus were divided into diabetic neuropathy group (n = 30) and diabetic neuropathy group (n = 30), and 30 healthy people were included as healthy control group. Serum S100β, MBP levels in the above study were detected by enzyme-linked immunosorbent assay. Results The positive rates of S100β and MBP in diabetic peripheral neuropathy group were significantly higher than those in healthy control group and non-neuropathic group (P <0.05). Conclusion Serum MBP and S100β protein may be one of the early diagnosis and follow-up indicators of diabetic peripheral neuropathy.